CAR T Therapies: Game Changer or Culprit in Cancer Treatment?‎

Main Article Content

Ali Afzal
Muhammad Babar Khawar


The FDA alerts to potential T cell malignancy risks linked to CAR T therapies targeting CD19/BCMA, recognizing their advantages but advocating vigilant monitoring. Influential factors in secondary T cell malignancy encompass viral vectors, CAR design, and patient genetics. Analytical findings highlight instances of T cell cancer, stressing the necessity for prolonged safety studies and refined CAR T strategies. Global collaboration is crucial for consistent reporting and adherence to treatments. Recommendations include extended safety assessments, refined CAR T strategies, enhanced data reporting, and global cooperation. This viewpoint addresses safety concerns regarding CAR T therapies and proposes measures to enhance their safety and effectiveness. The discussion emphasizes the importance of optimizing CAR T strategies to minimize risks and elevate treatment outcomes

Article Details

How to Cite
Afzal, A., & Khawar, M. B. (2024). CAR T Therapies: Game Changer or Culprit in Cancer Treatment?‎. Albus Scientia, 2024(1), 1–3.



Albelda, S. M. (2024). CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn. Nature Reviews Clinical Oncology, 21(1), 47-66. DOI:

Anand, K., Ensor, J., Pingali, S. R., Hwu, P., Duvic, M., Chiang, S., Miranda, R., Zu, Y., & Iyer, S. (2020). T-cell lymphoma secondary to checkpoint inhibitor therapy. Journal for Immunotherapy of Cancer, 8(1). DOI:

Banerjee, R., Poh, C., Hirayama, A. V., Gauthier, J., Cassaday, R. D., Shadman, M., Cowan, A. J., Till, B. G., Green, D. J., Kiem, H. P., Gopal, A. K., & Maloney, D. G. (2024). Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic. Blood Aadvances, 8(4), 895–898. DOI:

Cinquina, A., Feng, J., Zhang, H., & Ma, Y. (2022). CAR Therapy for T-cell Malignancies. Journal of Cellular Immunology, 4(4), 131-133. DOI:

Furlow, B. (2024). FDA investigates risk of secondary lymphomas after CAR-T immunotherapy. The Lancet Oncology, 25(1), 21. DOI:

Harrison, S. J., Nguyen, T., Rahman, M., Er, J., Li, J., Li, K., Lendvai, N., Schecter, J. M., Banerjee, A., & Roccia, T. (2023). CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma. Blood, 142, 6939. DOI:

Heinrich, T., Rengstl, B., Muik, A., Petkova, M., Schmid, F., Wistinghausen, R., Warner, K., Crispatzu, G., Hansmann, M.-L., & Herling, M. (2013). Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Molecular Therapy, 21(6), 1160-1168. DOI:

Jain, N., Zhao, Z., Feucht, J., Koche, R., Iyer, A., Dobrin, A., Mansilla-Soto, J., Yang, J., Zhan, Y., Lopez, M., Gunset, G., & Sadelain, M. (2023). TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature, 615(7951), 315-322. DOI:

Ji, Q., Wu, X., Zhang, Y., Zeng, L., Dong, Y., Liu, R., Li, B., Bai, Z., Hu, S., & Lu, J. (2024). Adverse events and efficacy of second‐round CAR‐T cell therapy in relapsed pediatric B‐ALL. European Journal of Haematology, 112(1), 75-82. DOI:

Khawar, M. B., Ge, F., Afzal, A., & Sun, H. (2023a). From barriers to novel strategies: smarter CAR T therapy hits hard to tumors. Frontiers in Immunology, 14, 1203230. DOI:

Khawar, M. B., Gao, G., Rafiq, M., Shehzadi, A., Afzal, A., Abbasi, M. H., Sheikh, N., Afzal, N., Ashraf, M. A., Hamid, S. E., Shahzaman, S., Kawish, N., & Sun, H. (2023b). Breaking down barriers: The potential of smarter CAR-engineered NK cells against solid tumors. Journal of Cellular Biochemistry, 124(8), 1082–1104. DOI:

Khawar, M. B., Afzal, A., Abbasi, M. H., Sheikh, N., & Sun, H. (2023c). Nano-Immunoengineering of CAR-T cell therapy against tumor microenvironment: The way forward in combating cancer. OpenNano, 10, 100124. DOI:

Levine, B. L., Pasquini, M. C., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J. J., Horwitz, E. M., Grupp, S. A., Maus, M. V., & Locke, F. L. (2024). Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine, 1-4. DOI:

Meadows, A. T., Friedman, D. L., Neglia, J. P., Mertens, A. C., Donaldson, S. S., Stovall, M., Hammond, S., Yasui, Y., & Inskip, P. D. (2009). Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. Journal of Clinical Oncology, 27(14), 2356. DOI:

Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., & Bishop, D. C. (2021). Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood, The Journal of the American Society of Hematology, 138(16), 1391-1405. DOI:

Savoldo, B., Grover, N., & Dotti, G. (2024). CAR T cells for hematological malignancies. The Journal of Clinical Investigation, 134(2). DOI:

Stewart, A. G., & Henden, A. S. (2021). Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 8, 20499361211036773. DOI:

Most read articles by the same author(s)